Guillain-Barre Syndrome (GBS) is a serious illness that often progresses rapidly, making the patient bedridden in a few days ...

The United States has officially pulled out from the Paris Climate Agreement, effective January 27, 2026. UN spokesperson, ...

The health officials said that a new Guillain-Barre Syndrome case was reported in Pune on Tuesday; number of suspected GBS ...

Cases of Chikungunya among children are being reported in recent days, Lady Ridgeway Hospital’s Consultant Paediatrician Dr. Deepal Perera said. Dr.

Maharashtra CM reviews GBS cases, instructs officials for treatment arrangements, and coverage under MJPJAY in government ...

When you think about infectionsclassically the thought runs to malariawith recent cases also in Italy, tuberculosis or HIV ...

Valneva’s growth potential lies in Ixchiq, but risks remain. Find out why VALN stock is still a Buy with a good long-term ...

Valneva’s vaccine was highly immunogenic in both dose groups. A full dose of the vaccine exhibited a more robust immune response compared to a half dose by providing protective antibody titers already ...

Valneva chikungunya vaccine shows strong, sustained immune response in adolescents, supporting potential approvals in Brazil and other regions.

The FDA is reviewing new vaccines for meningitis and chikungunya and therapies for Parkinson disease and PTSD.

Valneva has announced positive outcomes from its Phase III VLA1553-321 trial of the single-shot IXCHIQ chikungunya virus ...

Valneva (VALN) stock rose after the company posted new Phase 3 trial data for its chikungunya vaccine, Ixchiq, in adolescents aged 12-17. Read more here.